# Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

> **NCT04114825** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **RhoVac APS** · enrollment: 180 (estimated)

## Conditions studied

- Prostate Cancer Recurrent

## Interventions

- **BIOLOGICAL:** RV001V
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04114825
- **Lead sponsor:** RhoVac APS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-19
- **Primary completion:** 2022-04
- **Final completion:** 2022-11
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04114825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04114825, "Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04114825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*